#United States #New York #Rosen Law Firm #Securities Class Action #ADMA Biologics

Rosen Law Firm Urges ADMA Biologics Investors to Take Action

The Rosen Law Firm, known globally for its advocacy for investor rights, is currently conducting an investigation into potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). This inquiry is prompted by serious allegations that the firm may have provided significantly misleading business information to the public, affecting stock valuation and investor trust.

Background on the Investigation

On March 24, 2026, a substantial report from short seller Culper Research revealed critical claims against ADMA Biologics, alleging that the company engaged in channel stuffing practices to artificially inflate revenue growth. Following the publication of this report, ADMA’s stock suffered a significant decline, plummeting by 16.6%. This drastic drop raised red flags for many investors who began to question the transparency and accuracy of the information previously disclosed by the company.

The Rosen Law Firm is now encouraging all individuals who purchased ADMA Biologics securities to consider their eligibility to join a potential class action lawsuit. Importantly, no upfront fees or costs will be required from the investors, as the Rosen Law Firm operates under a contingency fee arrangement. In simpler terms, legal fees will only be incurred if the class action is successful in recovering losses for the investors.

Joining the Class Action

Interested parties can join this prospective class action by visiting the Rosen Law Firm's dedicated webpage at rosenlegal.com/submit-form or by contacting Phillip Kim, Esq., toll-free at 866-767-3653. Alternatively, investors can reach out via email at [email protected] for further information related to the class action.

Why Choose Rosen Law Firm

The Rosen Law Firm stands out due to its proven track record in leading securities class action lawsuits. The firm has successfully achieved significant settlements for investors and has been consistently recognized for its expertise in the field; it notably secured the largest-ever securities class action settlement against a Chinese company. This level of experience places the firm among the most sought-after choices for investors needing legal representation in cases of potential securities fraud.

In fact, the firm was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements obtained and has retained a top-four position since 2013. Just in 2019, they successfully recovered over $438 million for investors, showcasing their capability to deliver results.

Furthermore, Laurence Rosen, co-founder of the firm, received the prestigious title of “Titan of the Plaintiffs' Bar” from Law360 in 2020, underscoring the high level of respect and recognition the firm has garnered within legal and investment communities.

Stay Updated

For real-time updates regarding the investigation and further details about the class action, interested individuals are encouraged to follow the Rosen Law Firm on various social media platforms. They can be found on LinkedIn, Twitter, and Facebook.

Conclusion

The ongoing investigation into ADMA Biologics serves as a crucial reminder for investors to be vigilant and informed regarding the companies they choose to invest in. Those potentially affected by the misleading information surrounding ADMA Biologics are strongly urged to reach out to the Rosen Law Firm to explore their options for recovery. By doing so, investors take a proactive step towards protecting their financial interests in a challenging market environment.